In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells | Zendy

Dharminder Chauhan | Zendy; Arghya Ray | Zendy; Kristina Viktorsson | Zendy; Jack Spira | Zendy; Claudia E. PabaPrada | Zendy; Nikhil Munshi | Zendy; Paul Richardson | Zendy; Rolf Lewensohn | Zendy; Kenneth C. Anderson | Zendy

Open Access

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells

Author(s) -

Dharminder Chauhan,

Arghya Ray,

Kristina Viktorsson,

Jack Spira,

Claudia E. PabaPrada,

Nikhil Munshi,

Paul Richardson,

Rolf Lewensohn,

Kenneth C. Anderson

Publication year - 2013

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-12-3752

Subject(s) - melphalan , bortezomib , multiple myeloma , pharmacology , lenalidomide , cancer research , medicine , apoptosis , prodrug , angiogenesis , in vivo , chemistry , biology , immunology , biochemistry , microbiology and biotechnology

The alkylating agent melphalan prolongs survival in patients with multiple myeloma; however, it is associated with toxicities and development of drug-resistance. Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen), a novel dipeptide prodrug of melphalan in multiple myeloma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research